A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Clinical trial NCT04699877 · COMPLETED

Trial details

NCT number: NCT04699877
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Renal Impaired Gilteritinib Normal Renal Function Pharmacokinetics of ASP2215

Start date: 2021-01-28
Primary completion: 2022-07-18
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.